查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654296

精准肿瘤学市场规模、份额、趋势分析报告（依产品类型、癌症类型、最终用途、地区、细分预测），2025-2030 年

Precision Oncology Market Size, Share & Trends Analysis Report By Product Type (Diagnostics, Therapeutics), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

精准肿瘤学市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，到2030年全球精准肿瘤学市场规模预计将达到2019.6亿美元，2025年至2030年的复合年增长率为8.05%。

精准肿瘤学是一个正在发展的领域，其市场产品专注于肿瘤的分子分析以识别基因变异。目前，该行业取得了巨大的成功，患者的反应率达到 95%，同时质量调整生存期也延长了。市场产品有可能改善医院和诊所的患者照护并做出更明智的决策。此外，全球癌症发生率的不断上升、临床试验研究数量的不断增加以及精准肿瘤诊断技术的快速应用也有望推动市场需求。

由于全球癌症患者的医疗保健范围不断扩大并带来了独特的挑战，精准肿瘤学市场受到了 COVID-19 疫情的严重影响。而且，精准肿瘤诊断和治疗的延迟对癌症患者的诊断和治疗产生了重大影响。然而，在新冠疫情之后，精准肿瘤学能够提供更好的治疗效果并改善癌症患者的生活质量，因此市场需求正在迅速增长。

2022 年 1 月，OncXerna Therapeutics, Inc. 和 Exact Sciences Corp. 宣布达成协议，将 OncXerna 的 TME Panel化验服务带给美国患者。这是一个创新的基因表现评分，可以帮助识别对免疫疗法和抗血管新生疗法有反应的患者。该公司进一步补充说，它有信心透过其生物製药合作伙伴为临床医生提供 Xerna TME Panel，既作为伴同性诊断，也透过其现有的精准肿瘤学团队。

精准肿瘤学市场报告重点

  • 根据产品类型，由于针对特定基因突变的标靶治疗的持续开发和核准，治疗药物部门在 2024 年占据市场最大收入份额，为 71.3%。
  • 根据癌症类型，乳癌领域在 2024 年占据市场最大收益占有率，达 41.7%。
  • 根据最终用途，医院和诊断部门占据市场主导地位，2024 年的收益占有率最大，为 46.8%。在医院和诊断领域，精准肿瘤学产品正在全球范围内引起越来越多的关注，因为它们专注于肿瘤的分子分析以识别基因变异。
  • 2024 年北美精准肿瘤学市场占最大收益占有率，为 44.0%。该市场的主导地位归因于可实现个人化治疗方法的先进诊断工具的日益普及。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 精准肿瘤学市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 精准肿瘤学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL 分析

第四章精准肿瘤学市场：产品类型评估与趋势分析

  • 2024 年及 2030 年产品类型市场占有率
  • 细分仪表板
  • 全球精准肿瘤学市场依产品类型展望
  • 2018 年至 2030 年市场规模、预测及趋势分析
    • 诊断
    • 治疗

第五章精准肿瘤学市场：癌症类型估计与趋势分析

  • 2024 年和 2030 年各癌症类型的市场占有率
  • 细分仪表板
  • 全球精准肿瘤学市场按癌症类型展望
  • 2018 年至 2030 年市场规模、预测及趋势分析
    • 乳癌
    • 大肠直肠癌
    • 子宫颈癌
    • 摄护腺癌
    • 肺癌
    • 其他的

6. 精准肿瘤学市场：最终用途估计与趋势分析

  • 2024 年及 2030 年终端用途市场占有率
  • 细分仪表板
  • 全球精准肿瘤学市场前景（依最终用途）
  • 2018 年至 2030 年市场规模、预测及趋势分析
    • 医院及诊断
    • 製药和生物技术
    • 医疗保健资料公司

第七章精准肿瘤学市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018 年至 2030 年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • Key company market share analysis, 2024
    • Thermo Fisher Scientific Inc.
    • Invitae Corporation
    • Qiagen NV
    • Illumina, Inc.
    • Laboratory Corporation of America Holding
    • Exact Sciences Corporation
    • Rain Oncology Inc.
    • Strata Oncology Inc.
    • Xilis, Inc.
    • Variantyx, Inc.
    • Bioserve
    • Relay Therapeutics
    • Acrivon Therapeutics
Product Code: GVR-4-68040-032-5

Precision Oncology Market Growth & Trends:

The global precision oncology market size is expected to reach USD 201.96 billion by 2030, registering a CAGR of 8.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.

Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.

In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna's TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.

Precision Oncology Market Report Highlights:

  • Based on product type, the therapeutics segment led the market with the largest revenue share of 71.3% in 2024, due to the increasing development and approval of targeted treatments tailored to specific genetic mutations.
  • Based on cancer type, the breast cancer segment led the market with the largest revenue share of 41.7% in 2024, attributed to increasing awareness for breast cancer screening, diagnosis, and surgical and radiation techniques.
  • Based on end-use, the hospitals and diagnostic segment led the market with the largest revenue share of 46.8% in 2024. In hospital and diagnostic, precision oncology products are garnering an increasing amount of interest worldwide as it emphases molecular profiling of tumors to identify alterations in the gene.
  • North America precision oncology market dominated with the largest revenue share of 44.0% in 2024. The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Cancer Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type outlook
    • 2.2.2. Cancer type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Precision Oncology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Cancer
      • 3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
      • 3.2.1.3. Supportive Government and Private Sector Initiatives
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Costs of Precision Oncology Therapies
      • 3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
  • 3.3. Precision Oncology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Precision Oncology Market by Product Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Diagnostics
      • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Therapeutics
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Precision Oncology Market by Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Breast Cancer
      • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Colorectal Cancer
      • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Cervical Cancer
      • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Prostate Cancer
      • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Lung Cancer
      • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Precision Oncology Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Diagnostic
      • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.2. Pharmaceutical and Biotechnology
      • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Healthcare Data Companies
      • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Invitae Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Qiagen N.V.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Illumina, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Laboratory Corporation of America Holding
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Exact Sciences Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Rain Oncology Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Strata Oncology Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Xilis, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Variantyx, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bioserve
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Relay Therapeutics
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Acrivon Therapeutics
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 3 North America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 4 North America precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 U.S. precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 6 U.S. precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 7 U.S. precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 8 Canada precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 9 Canada precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 10 Canada precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 11 Mexico precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 12 Mexico precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 13 Mexico precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 14 Europe precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 15 Europe precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 16 Europe precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 17 UK precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 18 UK precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 19 UK precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 20 Germany precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 21 Germany precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 22 Germany precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 23 France precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 24 France precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 25 France precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 26 Italy precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 27 Italy precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 28 Italy precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 29 Spain precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 30 Spain precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 31 Spain precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 32 Denmark precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 33 Denmark precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 34 Denmark precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 35 Sweden precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 36 Sweden precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 37 Sweden precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 38 Norway precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 39 Norway precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 40 Norway precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 41 Asia Pacific precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 42 Asia Pacific precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 44 Japan precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 45 Japan precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 46 Japan precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 47 China precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 48 China precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 49 China precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 India precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 51 India precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 52 India precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 Australia precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 54 Australia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 55 Australia precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Thailand precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 57 Thailand precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 58 Thailand precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 South Korea precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 60 South Korea precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 61 South Korea precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 Latin America precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 63 Latin America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 64 Latin America precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Brazil precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 66 Brazil precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 67 Brazil precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Argentina precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 69 Argentina precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 70 Argentina precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 71 Middle East & Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 72 Middle East & Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 73 Middle East & Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 74 South Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 75 South Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 76 South Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 77 Saudi Arabia precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 78 Saudi Arabia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 79 Saudi Arabia precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 80 UAE precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 81 UAE precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 82 UAE precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 83 Kuwait precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 84 Kuwait precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 85 Kuwait precision oncology market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Precision Oncology: Market outlook
  • Fig. 9 Precision Oncology: Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Precision Oncology Market driver impact
  • Fig. 15 Precision Oncology Market Restraint Impact
  • Fig. 16 Precision Oncology Market Strategic Initiatives Analysis
  • Fig. 17 Precision Oncology market: Product type movement analysis
  • Fig. 18 Precision Oncology market: Product type outlook and key takeaways
  • Fig. 19 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Precision Oncology market: Cancer type movement analysis
  • Fig. 22 Precision Oncology market: Cancer type outlook and key takeaways
  • Fig. 23 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Cervical Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Precision Oncology market: End Use movement analysis
  • Fig. 30 Precision Oncology market: End Use outlook and key takeaways
  • Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical & Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Healthcare Data Companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 North America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.K. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)